Press Releases
16 February 2005
Start of the EV02 trial in Lausanne and London
Eurovacc started the phase I trial (EV02) in Lausanne and London to evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prima-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection.
7 June 2004
Results from EV01 trial in Lausanne and London
The results from the EV01 trial, to evaluate and safety and immunogenicity of NYVAC-C, showed that the vaccine is well tolerated and vaccine-induced T-cell responses were observed in 45% of the vaccine recipients.
